Cargando…

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

Cholestatic liver diseases encompass a wide spectrum of disorders with different causes, resulting in impaired bile flow and accumulation of bile acids and other potentially hepatotoxic cholephils. The understanding of the molecular mechanisms of bile formation and cholestasis has recently improved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halilbasic, Emina, Baghdasaryan, Anna, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Health Sciences Division 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633080/ https://www.ncbi.nlm.nih.gov/pubmed/23540496 http://dx.doi.org/10.1016/j.cld.2012.12.001

Ejemplares similares

Bile acid transporters and regulatory nuclear receptors in the liver and beyond
por: Halilbasic, Emina, et al.
Publicado: (2013)

Novel therapeutic targets for cholestatic and fatty liver disease
por: Trauner, Michael, et al.
Publicado: (2022)

Fibrosis in Autoimmune and Cholestatic Liver Disease
por: Penz-Österreicher, Melitta, et al.
Publicado: (2011)

Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology
por: Staufer, Katharina, et al.
Publicado: (2014)

Fine‐Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease
por: Blokker, Britt A., et al.
Publicado: (2019)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

Pathogenesis of primary sclerosing cholangitis
por: Pollheimer, Marion J., et al.
Publicado: (2011)

Cholestatic liver diseases: new targets, new therapies
por: Santiago, Priscila, et al.
Publicado: (2018)

Liver Transplantation for Patients with Cholestatic Liver Diseases
por: Schöning, Wenzel, et al.
Publicado: (2015)

Update on pharmacotherapies for cholestatic liver disease
por: Ali, Ahmad H., et al.
Publicado: (2016)

The Gut-Liver Axis in Cholestatic Liver Diseases
por: Blesl, Andreas, et al.
Publicado: (2021)

Review: Pathogenesis of cholestatic liver diseases
por: Yokoda, Raquel T, et al.
Publicado: (2020)

Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease
por: Lemberger, Ursula J., et al.
Publicado: (2016)

Human Hepatocellular response in Cholestatic Liver Diseases
por: Ortiz, Kimberly, et al.
Publicado: (2023)

Evaluation and Management of Chronic Cholestatic Liver Diseases
por: Rini, Sandra Surya, et al.
Publicado: (2023)

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH
por: Xu, Jun, et al.
Publicado: (2023)

Cholestatic liver diseases: An era of emerging therapies
por: Samant, Hrishikesh, et al.
Publicado: (2019)

The Role of Vitamin K in Cholestatic Liver Disease
por: Sultana, Halima, et al.
Publicado: (2021)

Fibrotic Events in the Progression of Cholestatic Liver Disease
por: Wu, Hanghang, et al.
Publicado: (2021)

Guidelines for the Management of Cholestatic Liver Diseases (2021)
por: Lu, Lungen
Publicado: (2022)

Severe Cholestatic Drug-Induced Liver Injury With Cephalosporin Use
por: Yang, Kevin, et al.
Publicado: (2022)

The Role of Liver Biopsy in Investigation of Cholestatic Liver Disease in Infancy
por: Chaudhry, Zoya, et al.
Publicado: (2019)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia
por: Koh, Hong, et al.
Publicado: (2018)

The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study
por: Poetter-Lang, Sarah, et al.
Publicado: (2018)

Maternal obesogenic diet enhances cholestatic liver disease in offspring
por: Thompson, Michael D., et al.
Publicado: (2022)

Clinical Characterization of Alagille Syndrome in Patients with Cholestatic Liver Disease
por: Semenova, Natalia, et al.
Publicado: (2023)

Vitamin D Nuclear Receptor Deficiency Promotes Cholestatic Liver Injury by Disruption of Biliary Epithelial Cell Junctions in Mice
por: Firrincieli, Delphine, et al.
Publicado: (2013)

Recent developments in the management of idiopathic cholestatic liver disease
por: Imam, Mohamad H., et al.
Publicado: (2012)

Current and future therapies for inherited cholestatic liver diseases
por: van der Woerd, Wendy L, et al.
Publicado: (2017)

Hypothalamus-Pituitary-Adrenal Dysfunction in Cholestatic Liver Disease
por: Petrescu, Anca D., et al.
Publicado: (2018)

Bile acid-mediated signaling in cholestatic liver diseases
por: Zeng, Jing, et al.
Publicado: (2023)

The Role of Inflammation in Cholestatic Liver Injury
por: Chen, Jie, et al.
Publicado: (2023)

In Vivo (1)H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T
por: Gajdošík, Martin, et al.
Publicado: (2020)

Clinical application of transcriptional activators of bile salt transporters()
por: Baghdasaryan, Anna, et al.
Publicado: (2014)

Cutaneous polyarteriitis nodosa with Grave’s disease and cholestatic liver disease
por: Vassileva, V, et al.
Publicado: (2011)

Mechanisms of Hepatic Cholestatic Drug Injury
por: Kolarić, Tea Omanović, et al.
Publicado: (2019)

Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist()
por: Malik, Adnan, et al.
Publicado: (2019)

Rescue of Graves Thyrotoxicosis-Induced Cholestatic Liver Disease Without Antithyroid Drugs: A Case Report
por: Yan, Lily D., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g0mterflbjj170i9r6lb210sa1